Abstract:Lung adenocarcinoma was diagnosed in a 57-year-old female never-smoker with a subpleural mass in right upper lobe and enlarged mediastinal lymph nodes. Targeted next-generation sequencing for 425 cancer-related genes was performed to evaluate the oncogenes at the primary site, and EGFR exon 20 insertion mutation (p.H773dup) was shown. Unfortunately, she progressed with brain metastasis, accompanied by pericardial effusion and an enlarged right supraclavicular lymph node despite definitive chemoradiotherapy. She benefitted from subsequent treatment with six cycles of pemetrexed-cisplatin combined with bevacizumab. Local progression at the primary site occurred right after two additional cycles of maintenance therapy. The patient received radiation for the primary site; however, repeat imaging 1 month later revealed multiple bilateral lung metastases. Third-line therapy using nivolumab was given, and the patient reported severe dry cough along with left lower abdominal pain after 6 weeks of treatment. She progressed with multiple lung, brain, liver, and omentum metastasis and an enlarged retroperitoneal lymph node (Fig. 1). Suspicious hyperprogressive disease (HPD) developed. Rebiopsy of the omentum lesion was conducted and the pathological analysis indicated NSCLC, not otherwise specified. In addition to the EGFR exon 20 insertion mutation, EGFR and v-myc avian myelocytomatosis viral oncogene homolog gene (MYC) amplification were observed in reassessment of the mutation profiling. Although albumin paclitaxel and apatinib, a highly selective vascular endothelial growth factor receptor 2 inhibitor, were administered, the patient still died of rapid systematic progression afterward. HPD is a paradoxical pattern of tumor progression with a disputed definition.1Lo Russo G. Moro M. Sommariva M. et al.Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade.Clin Cancer Res. 2019; 25: 989-999Crossref PubMed Scopus (256) Google Scholar, 2Kato S. Goodman A. Walavalkar V. Barkauskas D.A. Sharabi A. Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res. 2017; 23: 4242-4250Crossref PubMed Scopus (580) Google Scholar, 3Ferrara R. Mezquita L. Texier M. et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy.JAMA Oncol. 2018; 4: 1543-1552Crossref PubMed Scopus (464) Google Scholar The rate of occurrence of HPD in NSCLC ranges from 8% to 21%, and it is usually accompanied by extremely poor outcome, with the median overall survival being only 3 months. Questions of mechanism notwithstanding, it is reasonable to assume that immune checkpoint inhibitors (ICIs) might break the homeostatic state between the elimination and escape phases of cancer immunoediting, facilitating immune escape and accelerated tumor growth.4Champiat S. Ferrara R. Massard C. et al.Hyperprogressive disease: recognizing a novel pattern to improve patient management.Nat Rev Clin Oncol. 2018; 15: 748-762Crossref PubMed Scopus (247) Google Scholar Older age and high metastatic burden before immunotherapy are associated with HPD.3Ferrara R. Mezquita L. Texier M. et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy.JAMA Oncol. 2018; 4: 1543-1552Crossref PubMed Scopus (464) Google Scholar In addition, MDM2 proto-oncogene gene (MDM2)/MDM4 regulator of p53 gene (MDM4) amplification, EGFR E746_A750del and T790M mutation, and gene amplification on the chromosome 11q13 are significantly correlated with HPD.2Kato S. Goodman A. Walavalkar V. Barkauskas D.A. Sharabi A. Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res. 2017; 23: 4242-4250Crossref PubMed Scopus (580) Google Scholar The accumulated evidence indicates that EGFR-mutated tumors usually predict a less satisfactory rate of response to ICIs. EGFR exon 20 insertion is the most common atypical EGFR mutation (4%–9.2%) and is known to confer resistance to current clinically available EGFR tyrosine kinase inhibitors. The relationship between EGFR exon 20 insertion and ICI-induced HPD is unknown. Our case is the first to report that nivolumab triggered HPD, leading to rapid death in a patient having EGFR exon 20 insertion mutation and MYC amplification. A very recent study provided direct evidence that treatment with nivolumab boosted EGFR-mutated tumor growth through interaction with M2-like macrophages.1Lo Russo G. Moro M. Sommariva M. et al.Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade.Clin Cancer Res. 2019; 25: 989-999Crossref PubMed Scopus (256) Google Scholar The emerging MYC amplification that was demonstrated in our patient was also suggested to contribute to tumor growth by upregulating CD47 molecule and programmed death ligand 1 expression.5Casey S.C. Tong L. Li Y. et al.MYC regulates the antitumor immune response through CD47 and PD-L1.Science. 2016; 352: 227-231Crossref PubMed Scopus (750) Google Scholar In addition, using the Kyoto Encyclopedia of Genes and Genomes and Gene Ontology database, we analyzed the mutation profiles before and after ICI administration. No other immune-related signaling pathway was involved. In this regard, EGFR aberrations and MYC amplification are considered as the potential mechanism explaining why HPD developed in our case. Administration of ICI monotherapy in this subgroup of patients must be performed with caution. This work was supported by the National Natural Science Foundation of China (grant 81870022) and the Medical and Health Technology Program of Zhejiang Province (grant 2017204226) to Dr. Xia.

Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature

Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature

Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement

Unleashing precision: A review of targeted approaches in pleural mesothelioma

Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

Treatment of Nivolumab Results in Hyperprogressive Disease in a Patient Harboring EGFR Exon 20 Insertion and MYC Amplification

Anti-PD-1 monotherapy in patients with malignant mesothelioma: A retrospective single institution experience.

Clinical Analysis of Combined Immunotherapy in Patients with Malignant Pleural Mesothelioma

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors

Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy

Characterization of Pleural Mesothelioma by Hierarchical Clustering Analyses Using Immune Cells within Tumor Microenvironment

Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting

Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study

Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma

Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors

Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report

Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment